BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15482138)

  • 1. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
    Gallant JE; Pham PA
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):415-22. PubMed ID: 15482138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate for the treatment of HIV infection.
    Pham PA; Gallant JE
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
    Lyseng-Williamson KA; Reynolds NA; Plosker GL
    Drugs; 2005; 65(3):413-32. PubMed ID: 15669881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir disoproxil fumarate.
    Grim SA; Romanelli F
    Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
    Frampton JE; Croom KF
    Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
    Adusumilli S
    Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate (Viread).
    Porche DJ
    J Assoc Nurses AIDS Care; 2002; 13(3):100-2. PubMed ID: 12064015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
    Kearney BP; Flaherty JF; Shah J
    Clin Pharmacokinet; 2004; 43(9):595-612. PubMed ID: 15217303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
    Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate.
    Chapman T; McGavin J; Noble S
    Drugs; 2003; 63(15):1597-608. PubMed ID: 12887265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of tenofovir use in HIV-infected children.
    Aurpibul L; Puthanakit T
    Pediatr Infect Dis J; 2015 Apr; 34(4):383-91. PubMed ID: 25247583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Goicoechea M; Best B
    Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.